Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2018-08-15 Regulatory Filings
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company was unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2018 on time and requests additional time to file it. The document does not contain the actual financial data or the quarterly report itself, but rather is a notification about the delay in filing the report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document related to filing deadlines and does not contain substantive financial information or the report itself.
2018-08-15 English
Regulatory Filings 2018
Regulatory Filings
2018-07-27 English
REGISTRATION STATEMENT
M&A Activity Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, dated July 23, 2018. It is a detailed registration statement under the Securities Act of 1933 related to a merger transaction involving American BriVision (Holding) Corporation and two other companies, BioLite and BioKey. The document includes extensive information about the merger agreement, merger consideration, risk factors, management discussion and analysis, pro forma financial data, legal matters, and other disclosures typical of merger-related filings. Form S-4 is specifically used for registration of securities issued in connection with mergers and acquisitions. This is not a typical annual report, earnings release, or proxy statement, but a comprehensive merger registration statement. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category 'M&A Activity' (Code: TAR). Therefore, this document should be classified as M&A Activity (TAR). The document length and content confirm it is the full filing, not just an announcement or a certification, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2018-07-23 English
REGISTRATION WITHDRAWAL REQUEST
Regulatory Filings Classification · 100% confidence The document is a formal letter addressed to the SEC requesting withdrawal of a Registration Statement on Form S-1. It references regulatory rules under the Securities Act of 1933 and states that the Registration Statement has not been declared effective and no securities were sold. The document is a regulatory communication about the withdrawal of a filing, not a financial report, earnings release, or other types of filings. It is short (2274 characters) and serves as a formal notice to the SEC rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2018-06-12 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2018
2018-05-15 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 10, 2018, reporting the departure of the Chief Financial Officer and the appointment of an interim CFO. The content focuses on management changes, specifically the resignation of a CFO and appointment of an interim CFO, with details about the new interim CFO's background and board approval. There are no financial statements or detailed financial data presented. The primary subject is changes in senior management and board-related information. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 4529 characters, which is sufficient to contain substantive information about management changes, not just a brief announcement. Therefore, the correct classification is MANG with high confidence.
2018-05-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.